Our Story and Vision:
Advancing the Future of Psychedelic Medicine with Experience & Integrity
.jpg)
At Psychedelic Science Institute (PSI) and our TRIP Clinics, we believe psychedelic-assisted therapy and psychedelic medicines hold transformative potential for mental health care and neuroscience.
After decades of scientific research, several psychedelic medicines, including psilocybin, MDMA, and LSD, are among the first neuroplasticity-based therapies (neuroplastogens) approaching potential FDA approval for conditions such as depression, anxiety, PTSD, and addiction. Together with growing scientific, clinical, and public policy support, the field is entering a historic new phase as these therapies move from clinical trials toward real-world patient care.
Our Vision:
A healthcare system where psychedelic medicines and related neuroplasticity-based therapies are trusted, evidence-based standards of care that improve lives and expand human potential.
Our Mission:
To advance the science and build the care delivery models that bring psychedelic medicines and related neuroplasticity-based therapies safely and equitably into mainstream healthcare.
Our Core Values
Patient Safety & Clinical Quality
We never compromise on our commitment to safe, ethical, high-quality care. Every decision begins with protecting the well-being of those we serve.
Scientific Rigor
We advance health through rigorous research, innovation, and a commitment to generating evidence that improves care.
Compassionate Care
We care for the whole person with empathy, dignity, and respect, recognizing that healing is deeply personal.
Equitable Access
We work to expand access to transformative health care so more people and communities can benefit.
Operational Excellence
We build disciplined, scalable, compliant, and financially sustainable systems that enable exceptional care, rigorous research, and lasting impact.
Interconnectedness
We honor the profound connections among people, communities, and the natural world, recognizing that lasting healing depends on the health of the systems that sustain us.
PSI emerged from the unification of two pioneering organizations in Southern California:
- The Pacific Neuroscience Institute’s Treatment & Research In Psychedelics (TRIP) Center, launched in Santa Monica in 2019. PNI has a decade-long record of delivering cutting-edge neuroscience and mental health care, including extensive experience conducting clinical trials across 10 Centers of Excellence.
- The California Center for Psychedelic Therapy (CCPT), established in Larchmont in 2018. CCPT was the first center in Southern California to offer psychedelic-assisted psychotherapy under the care of licensed psychiatrists and board-registered mental health professionals. It is also the region’s longest-standing provider of ketamine-assisted psychotherapy.
- Our founders, Daniel Kelly, MD, Keith Heinzerling, MD, Brooke Balliett, LMFT, Micah Linton, PsyD, and Greg Kearns, MHA, are internationally recognized leaders in clinical neuroscience, mental health, psychedelic-assisted therapy, and healthcare strategy.
- In 2025, with support from the nonprofit Psychedelic Innovation Fund, the teams at TRIP and CCPT came together to form PSI. Through this merger, we are building a new, sustainable model of mental health care grounded in research, compassion, and real-world impact.
PSI and TRIP Clinics are dedicated to:
- Developing safe and effective FDA-approved psychedelic-assisted therapies for conditions such as anxiety, depression, addiction, PTSD, bipolar disorder, and other behavioral health challenges.
- Advancing psychedelic science and understanding the neuroplastogenic potential of psychedelic medicines to change behavior, improve brain health, and optimize quality of life.
- Expanding access to psychedelic-assisted therapies for all those in need, including underserved and under-represented communities. We are proud to be an LGBTQIA+ and BIPOC-affirming practice, committed to inclusive care that helps patients and communities thrive. We don't just talk access, we deliver it.
- Training the next generation of clinicians and researchers in psychedelic medicine and educating the medical community and public on the potential impact of psychedelic-assisted therapies and the evolving field of psychedelic science.
Structured, Human, and Safe Care
At PSI, we are not just offering psychedelic therapy; we are helping define its future. Our dual-path model integrates real-world clinical care with rigorous clinical research to help shape the next decade of psychedelic medicine.
Ketamine-Assisted Psychotherapy (KAP):
A structured, supervised program for those facing depression, trauma, or chronic pain, led by clinicians with decades of experience in ketamine therapy.
Psychedelic-Assisted Clinical Trials:
Join a trial and help move psychedelic medicine forward. Our research spans conditions like treatment-resistant depression and PTSD. All trials are medically supervised and patient-centered.
Our Approach to Care
Patient-Centricity
Patients remain in control with full understanding, consent and freedom to pause or opt out at any time. We emphasize preparation, supervised dosing, and post-session integration within a “set and setting” model.
Clarity
We communicate clearly, offering facts, education, and support to help patients understand options and form realistic expectations.
Diversity
As one of the most active psychedelic trial and treatment sites in the US, we understand the importance of inclusion of all identities in our work. We are honored to serve a diverse population of participants, including members of the BIPOC and LGBTQIA+ communities.
Take the Next Step
You don’t have to have it all figured out.
Discover our medically supervised care options.
See what care is right for you.